14-3-3η Protein: Extracellular 14-3-3η Perpetuates Disease
Extracellular 14-3-3η protein is a potent ligand and activator of intracellular signalling pathways that lead to the up-regulation of inflammation and joint damage factors involved in RA pathogenesis. The 14-3-3η blood test is clinically available as a diagnostic test whereby a positive result indicates a 5 to 50 times greater likelihood of having RA and informs joint damage prognosis and disease monitoring. 14-3-3η is used alone, or in combination with other serological tests and clinical assessment to support RA patient management.
- 14-3-3η is a Novel Mediator Associated with the Pathogenesis of Rheumatoid Arthritis and Joint Damage
- Review: 14-3-3η – a Novel Biomarker Platform for Rheumatoid Arthritis
- Serum 14-3-3η is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis
- 14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis
- Serum 14-3-3η Level is Associated with Severity and Clinical Outcomes of Rheumatoid Arthritis, and its Pretreatment Level is Predictive of DAS28 Remission with Tocilizumab
- Decrease in 14-3-3η Protein Levels is Correlated with Improvement in Disease Activity in Patients with Rheumatoid Arthritis Treated with Tofacitinib